The TransBioLine WP4 (Biomarkers of vascular injury) Letter of Intent was accepted by the FDA on February 2020 and the team is in preparation to discuss the FDA recommendations to support the next stage, the Qualification Package, during the second quarter of 2020. Press here to download the LOI decision letter.